Company / Cost of Revenue
Aclaris Therapeutics, Inc. Cost of Revenue History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$2.1M
FY2025
5-year range
$2.1M / $4.7M
FY2021-FY2025
Trend
-38.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has fluctuated over the past 9 years, ranging from $1M in FY2019 to $5M in FY2023.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -13.5%.
Improved from $5M to $2M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -19.6%
- 5-Year CAGR
- -13.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -13.5%, indicating a declining trend.
- In FY2025, cost of revenue decreased 38.9% year-over-year.
- Peak cost of revenue was recorded in FY2023.
- Lowest cost of revenue in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1M | -38.9% |
| FY2024 | $3.4M | -27.4% |
| FY2023 | $4.7M | +17.2% |
| FY2022 | $4.0M | -14.6% |
| FY2021 | $4.7M | +8.9% |
| FY2020 | $4.3M | +258.7% |
| FY2019 | $1.2M | -72.1% |
| FY2018 | $4.3M | +258.7% |
| FY2017 | $1.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026